DURHAM, N.C., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that the Company’s second quarter 2014 financial results will be released after market close on Wednesday, August 13, 2014. Argos executive management will host a conference call beginning at 4:30 p.m. Eastern Time to discuss these results and to answer questions.
To participate by telephone, please dial (855) 433-0930 (Domestic) or (484) 756-4271 (International). The conference ID number is 77035844. A live and archived audio webcast can be accessed through the Investors section of the Company’s website at www.argostherapeutics.com. The archived webcast will remain available on the Company’s website for fourteen (14) days following the call.
About Argos Therapeutics
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos’ most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The company also plans to report data from its Phase 2b clinical trial of AGS-004 for the treatment of HIV in the third quarter of 2014. AGS-004 is being evaluated in a Phase 2a clinical trial for HIV eradication in adult patients. For more information about Argos Therapeutics, visit www.argostherapeutics.com.
CONTACT: Media: Jen Ringler Berry & Company Public Relations jringler@berrypr.com (212) 253-8881 Investors: Angeli Kolhatkar Burns McClellan akolhatkar@burnsmc.com (212) 213-0006
Help employers find you! Check out all the jobs and post your resume.
